Teva/Ivax: Generics' Answer to Big Pharma

Bigger generics companies aren't just the generic sector's problem. Giants such as the new Teva will present more formidable challenges to innovators, not just in patent wars but also with proprietary launches, and for a share of drug consumption in developing markets.

More from Business Strategy

More from In Vivo